STOCK TITAN

Kazia Therapeutics: ADAR1 reports 6.2% passive stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Kazia Therapeutics Ltd (KZIA) is the issuer in a reported beneficial-ownership position attributed to ADAR1 Capital Management, LLC and its sole manager, Daniel Schneeberger. Each reporting person lists 967,740 American Depositary Shares (ADSs), or 6.2%, with shared voting and dispositive power; the ADSs are held directly by private investment funds managed by ADAR1. The position is as of September 30, 2026.

Those funds also hold warrants exercisable for 1,615,705 ADSs, which are excluded from reported ownership because the warrants are subject to a 4.99% beneficial ownership limitation. The 6.2% figure uses 15,548,878 ADSs outstanding, as referenced in the issuer’s prospectus supplement dated August 28, 2026; each ADS represents 500 ordinary shares.

Beneficially owned ADSs 967,740 ADSs Reported by each reporting person with shared voting and dispositive power.
Ownership percentage 6.2% Based on 15,548,878 ADSs outstanding.
ADSs underlying warrants 1,615,705 ADSs Series A and Series B warrants held by funds managed by ADAR1; excluded from reported ownership.
Beneficial ownership limitation 4.99% Applies to the warrants and ADSs issuable upon exercise.
ADSs outstanding 15,548,878 ADSs Basis for the reported ownership percentage, as referenced in the prospectus supplement dated August 28, 2026.
Ordinary shares per ADS 500 ordinary shares Each American Depositary Share represents this number of ordinary shares.
American Depositary Shares technical
"American Depositary Shares, each representing five-hundred Ordinary Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
beneficial ownership limitations financial
"warrants are subject to 4.99% beneficial ownership limitations"
Beneficial ownership limitations are rules or contractual caps that restrict how much of a company’s stock an individual or entity can be treated as owning or controlling for legal, regulatory or corporate-governance purposes. They matter to investors because such limits affect voting power, reporting obligations, takeover risk and the ability to increase a stake — like an elevator weight limit or a lane divider that prevents any one car from taking over the whole road.
shared voting power technical
"Shared Voting Power 967,740.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power technical
"Shared Dispositive Power 967,740.00"
Series A and Series B warrants financial
"hold Series A and Series B warrants exercisable for 1,615,705 Depositary Shares"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KZIA ADSs did ADAR1 and Daniel Schneeberger report?

Each reported beneficial ownership of 967,740 ADSs, or 6.2%, with shared voting and dispositive power; the ADSs are directly owned by private investment funds managed by ADAR1.

How many KZIA ADSs are underlying warrants held by ADAR1-managed funds?

The funds hold Series A and Series B warrants exercisable for 1,615,705 ADSs. Those ADSs are excluded from reported ownership because the warrants are subject to a 4.99% beneficial ownership limitation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





48669G303

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 967,740 American Depositary Shares ("Depositary Shares"), each representing five hundred ordinary shares ("Ordinary Shares"), of Kazia Therapeutics Limited (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC ("ADAR1"). Such securities may be deemed to be indirectly beneficially owned by ADAR1. In addition to the Depositary Shares reported above, certain private investment funds managed by ADAR1 hold Series A and Series B warrants exercisable for 1,615,705 Depositary Shares. The Depositary Shares issuable upon exercise of these warrants are excluded from the amounts reported in boxes 6, 8, 9 and 11 because such warrants are subject to 4.99% beneficial ownership limitations determined in relation to the number of Ordinary Shares underlying the Depositary Shares. The percentage in box 11 is based on 15,548,878 Depositary Shares outstanding (representing 7,774,439,234 Ordinary Shares; each Depositary Share represents 500 Ordinary Shares) of the Issuer, as referenced in the Issuer's prospectus supplement dated August 28, 2026, filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on August 31, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 967,740 American Depositary Shares ("Depositary Shares"), each representing five hundred ordinary shares ("Ordinary Shares"), of Kazia Therapeutics Limited (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC ("ADAR1"). Such securities may be deemed to be indirectly beneficially owned by Daniel Schneeberger, the sole manager of ADAR1. In addition to the Depositary Shares reported above, certain private investment funds managed by ADAR1 hold Series A and Series B warrants exercisable for 1,615,705 Depositary Shares. The Depositary Shares issuable upon exercise of these warrants are excluded from the amounts reported in boxes 6, 8, 9 and 11 because such warrants are subject to 4.99% beneficial ownership limitations determined in relation to the number of Ordinary Shares underlying the Depositary Shares. The percentage in box 11 is based on 15,548,878 Depositary Shares outstanding (representing 7,774,439,234 Ordinary Shares; each Depositary Share represents 500 Ordinary Shares) of the Issuer, as referenced in the Issuer's prospectus supplement dated August 28, 2026, filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on August 31, 2026.


SCHEDULE 13G



ADAR1 Capital Management, LLC
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:11/16/2026
Daniel Schneeberger
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:11/16/2026
Exhibit Information

Exhibit A: Joint Filing Agreement

Keep reading